The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.

Cigna Group closed $14.69 short of its 52-week high ($370.83), which the company reached on September 16th.

The three price benefit managers jointly administer 80% of all prescriptions in the U.S., the FTC said in the lawsuit.

Bloomberg Washington Correspondents Joe Mathieu and Kailey Leinz deliver insight and analysis on the latest headlines from ...

The Federal Trade Commission (FTC) is suing pharmacy benefit managers CVS Health (CVS), Cigna Group (CI), and UnitedHealth ...

The Federal Trade Commission has brought an administrative complaint against three of the country's largest pharmacy benefit ...

The Federal Trade Commission has accused three major pharmacy benefit managers of inflating insulin prices, the agency said ...

On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...

The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged ...

The US Federal Trade Commission sued units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. on Friday, accusing ...

The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies ...

The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive ...